

<b>Product Name</b>	: Halofuginone
<b>Synonyms</b>	: RU 19110; RU19110; Halofuginone; Tempostat
<b>Cat No.</b>	: M17543
<b>CAS Number</b>	: 55837-20-2
<b>Molecular Formula</b>	: C <sub>16</sub> H <sub>17</sub> BrClN <sub>3</sub> O <sub>3</sub>
<b>Formula Weight</b>	: 414.68
<b>Chemical Name</b>	: 7-bromo-6-chloro-3-((2S,3R)-3-hydroxypiperidin-2-yl)-2-oxopropyl)quinazolin-4(3H)-one.
<b>Description</b>	<p>Halofuginone, also known as RU-19110, is a semisynthetic quinazolinone alkaloid anticoccidial derived from the plant <i>Dichroa febrifuga</i>, with antifibrotic and potential antineoplastic activities. Halofuginone specifically inhibits collagen type I gene expression and matrix metalloproteinase 2 (MMP-2) gene expression, which may result in the suppression of angiogenesis, tumor stromal cell development, and tumor cell growth. These effects appear to be due to halofuginone-mediated inhibition of the collagen type I and MMP-2 promoters.</p>
<b>Pathway</b>	: Metabolic Enzyme/Protease
<b>Target</b>	: Retinoid Receptor
<b>Receptor</b>	: prolyl-tRNA synthetase
<b>Solubility</b>	: DMSO : 9 mg/mL. 21.70 mM;
<b>SMILES</b>	: <chem>C1C[C@H]([C@@H](NC1)CC(=O)Cn1cnc2cc(c(cc2c1=O)Cl)Br)O</chem>
<b>Storage</b>	: (-20°C)
<b>Stability</b>	: ≥ 2 years
<b>Reference</b>	:

1. Runlong Lin, et al. *Onco Targets Ther.* 2015; 8: 3549–3559.